These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29391076)

  • 1. Gamunex® in Guillain-Barré Syndrome: A Postmarketing, Retrospective, Observational Study.
    Siddiqi ZA; Courtney K; Hanna K; Mondou E; Bril V
    Can J Neurol Sci; 2017 Nov; 44(6):711-717. PubMed ID: 29391076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin and Guillain-Barré syndrome.
    Harel M; Shoenfeld Y
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):281-7. PubMed ID: 16391403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study.
    Verboon C; van den Berg B; Cornblath DR; Venema E; Gorson KC; Lunn MP; Lingsma H; Van den Bergh P; Harbo T; Bateman K; Pereon Y; Sindrup SH; Kusunoki S; Miller J; Islam Z; Hartung HP; Chavada G; Jacobs BC; Hughes RAC; van Doorn PA;
    J Neurol Neurosurg Psychiatry; 2020 Feb; 91(2):113-121. PubMed ID: 31586949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guillain-Barré syndrome following chickenpox: a case series.
    Tatarelli P; Garnero M; Del Bono V; Camera M; Schenone A; Grandis M; Benedetti L; Viscoli C
    Int J Neurosci; 2016; 126(5):478-9. PubMed ID: 26000930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.
    Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; van den Berg B; Doets AY; Leonhard SE; Verboon C; Huizinga R; Drenthen J; Arends S; Budde IK; Kleyweg RP; Kuitwaard K; van der Meulen MFG; Samijn JPA; Vermeij FH; Kuks JBM; van Dijk GW; Wirtz PW; Eftimov F; van der Kooi AJ; Garssen MPJ; Gijsbers CJ; de Rijk MC; Visser LH; Blom RJ; Linssen WHJP; van der Kooi EL; Verschuuren JJGM; van Koningsveld R; Dieks RJG; Gilhuis HJ; Jellema K; van der Ree TC; Bienfait HME; Faber CG; Lovenich H; van Engelen BGM; Groen RJ; Merkies ISJ; van Oosten BW; van der Pol WL; van der Meulen WDM; Badrising UA; Stevens M; Breukelman AJ; Zwetsloot CP; van der Graaff MM; Wohlgemuth M; Hughes RAC; Cornblath DR; van Doorn PA;
    Lancet Neurol; 2021 Apr; 20(4):275-283. PubMed ID: 33743237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional outcomes following inpatient rehabilitation of Guillain-Barré syndrome patients: Intravenous immunoglobulins versus plasma exchange.
    Bondi M; Engel-Haber E; Wolff J; Grosman-Rimon L; Bloch A; Zeilig G
    NeuroRehabilitation; 2021; 48(4):543-551. PubMed ID: 34024788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient characteristics and the effects of intravenous immunoglobulin in patients with Guillain-Barre syndrome.
    Guzey Aras Y; Tanik O; Dogan Güngen B; Kotan D
    Ideggyogy Sz; 2016 Nov; 69(11-12):389-395. PubMed ID: 29733556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency.
    Oczko-Walker M; Manousakis G; Wang S; Malter JS; Waclawik AJ
    J Clin Neuromuscul Dis; 2010 Dec; 12(2):55-61. PubMed ID: 21386771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose immunoglobulin therapy for Guillain-Barré syndrome in Japanese children.
    Yata J; Nihei K; Ohya T; Hirano Y; Momoi M; Maekawa K; Sakakihara Y;
    Pediatr Int; 2003 Oct; 45(5):543-9. PubMed ID: 14521529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of plasma exchange versus intravenous immunoglobulin for the treatment of Guillain-Barré Syndrome: A double-blind, randomized clinical trial.
    Haridy NA; Shehab MM; Khedr EM
    Restor Neurol Neurosci; 2023; 41(5-6):203-217. PubMed ID: 38217554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA; Raphaël JC; Swan AV; van Doorn PA
    Cochrane Database Syst Rev; 2001; (2):CD002063. PubMed ID: 11406030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study.
    Verboon C; Harbo T; Cornblath DR; Hughes RAC; van Doorn PA; Lunn MP; Gorson KC; Barroso F; Kuwabara S; Galassi G; Lehmann HC; Kusunoki S; Reisin RC; Binda D; Cavaletti G; Jacobs BC; ;
    J Neurol Neurosurg Psychiatry; 2021 Oct; 92(10):1080-1088. PubMed ID: 34103340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-existent ulcerative colitis and Guillain-Barré syndrome: a case report and literature review.
    Tominaga K; Tsuchiya A; Sato H; Kimura A; Oda C; Hosaka K; Kawata Y; Kimura N; Hayashi K; Yokoyama J; Terai S
    Clin J Gastroenterol; 2019 Jun; 12(3):243-246. PubMed ID: 30778832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin.
    Tsai CP; Wang KC; Liu CY; Sheng WY; Lee TC
    J Clin Neurosci; 2007 Jul; 14(7):625-9. PubMed ID: 17532498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barrè syndrome long-term outcome: a retrospective study.
    Prada V; Massa F; Salerno A; Fregosi D; Beronio A; Serrati C; Mannironi A; Mancardi G; Schenone A; Benedetti L
    Neurol Sci; 2020 Feb; 41(2):321-327. PubMed ID: 31586288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barré Syndrome.
    Fokkink WR; Walgaard C; Kuitwaard K; Tio-Gillen AP; van Doorn PA; Jacobs BC
    JAMA Neurol; 2017 Feb; 74(2):189-196. PubMed ID: 28027337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin therapy for HIV-associated Guillain-Barré syndrome.
    Wang J; Zhang Y; Wang M; Ren Y; Tang M; Liu L; Zhou D
    Int Immunopharmacol; 2022 Nov; 112():109192. PubMed ID: 36155283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins.
    Fokkink WJ; Selman MH; Dortland JR; Durmuş B; Kuitwaard K; Huizinga R; van Rijs W; Tio-Gillen AP; van Doorn PA; Deelder AM; Wuhrer M; Jacobs BC
    J Proteome Res; 2014 Mar; 13(3):1722-30. PubMed ID: 24533874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Efficacy of Intravenous Immunoglobulin in Guillain-Barré Syndrome: The Experience of a Tertiary Medical Center.
    Shalem D; Shemer A; Shovman O; Shoenfeld Y; Kivity S
    Isr Med Assoc J; 2018 Dec; 20(12):754-760. PubMed ID: 30550005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The usefulness of chief complaints to predict severity, ventilator dependence, treatment option, and short-term outcome of patients with Guillain-Barré syndrome: a retrospective study.
    Wang Y; Shang P; Xin M; Bai J; Zhou C; Zhang HL
    BMC Neurol; 2017 Nov; 17(1):200. PubMed ID: 29157205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.